Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign prostatic hyperplasia. Early recognition and management.

D A Culp

    The Urologic Clinics of North America
    |February 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Carcinoma of the prostate gland; an analysis of 135 consecutive cases.

    Pennsylvania medical journal (1928)·2010
    Same author

    Effects of adrenergic antagonists on cocaine-induced changes in respiratory function.

    Pulmonary pharmacology·1991
    Same author

    Yield of cancer tissue from prostatic needle biopsy.

    Urology·1987
    Same author

    Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.

    Urology·1986
    Same author

    Cystadenocarcinoma of the kidney: a profile of 13 cases.

    The Journal of urology·1985
    Same author

    Radical prostatectomy with adjuvant radioactive gold for prostatic cancer: a preliminary report.

    The Journal of urology·1985
    Same journal

    An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

    The Urologic clinics of North America·2026
    Same journal

    Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

    The Urologic clinics of North America·2026
    Same journal

    Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

    The Urologic clinics of North America·2026
    Same journal

    Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

    The Urologic clinics of North America·2026
    Same journal

    Economic Considerations in the Management of Superficial Bladder Cancer.

    The Urologic clinics of North America·2026
    Same journal

    Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

    The Urologic clinics of North America·2026
    See all related articles

    Medical management for prostatic hyperplasia is still experimental. Early studies show hormonal therapies like cyproterone acetate may improve symptoms and reduce prostate size, but surgery remains the primary treatment for benign prostatic hyperplasia.

    Area of Science:

    • Urology
    • Endocrinology

    Background:

    • Medical management for benign prostatic hyperplasia (BPH) is largely investigational.
    • Hormonal therapies are being explored for their potential to inhibit prostate growth and alleviate symptoms.

    Purpose of the Study:

    • To review the current status of medical management for BPH.
    • To highlight preliminary findings on hormonal agents, specifically cyproterone acetate.

    Main Methods:

    • Review of existing literature on medical therapies for BPH.
    • Analysis of a specific study involving cyproterone acetate in patients with nodular hyperplasia.

    Main Results:

    • Cyproterone acetate showed positive effects in 13 patients with nodular hyperplasia, improving obstructive symptoms, flow rate, and reducing residual urine and prostate size.

    Related Experiment Videos

  • Histological changes were also observed in the prostate epithelium.

    • Conclusions:

    • While hormonal therapies show promise, their long-term efficacy and role in BPH management require further investigation.
    • Prostatectomy remains the standard surgical treatment for BPH due to its established effectiveness and low mortality rate.